Results of a planned efficacy and safety analysis for a National Comprehensive Cancer Network sponsored phase II study of gemcitabine and irinotecan (GI) in metastatic breast cancer (MBC) Mammographic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results